drugset / Trial / NCT00444340

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

NCT00444340

Phase 4 Completed 70 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.

Timeline

Start
2004-04
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic